NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free BEAM Stock Alerts $33.04 -0.92 (-2.71%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$32.92▼$34.1750-Day Range$23.69▼$45.0752-Week Range$16.95▼$49.50Volume1.33 million shsAverage Volume1.38 million shsMarket Capitalization$2.70 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Beam Therapeutics alerts: Email Address Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside24.1% Upside$41.00 Price TargetShort InterestBearish17.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 13 Articles This WeekInsider TradingSelling Shares$1.62 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.50) to ($5.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 starsMedical Sector795th out of 938 stocksBiological Products, Except Diagnostic Industry127th out of 148 stocks 3.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Beam Therapeutics has a forecasted upside of 24.1% from its current price of $33.04.Amount of Analyst CoverageBeam Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.54% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 2.3 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 26 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat Follows12 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,618,322.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($5.50) to ($5.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -17.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -17.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesMarch 9, 2024 | marketbeat.comMarketBeat Week in Review – 3/4 – 3/8 (BEAM)The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hotMarch 6, 2024 | marketbeat.comBeam Therapeutics Bolts Higher on Gene Therapy Licensing PaymentsBeam Therapeutics Inc. NASDAQ: BEAM is a biotech company that specializes in developing precision gene therapies for hereditary diseases. The medical sector company is a pioneer in a proprietary gene-editing technique called base editing.March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 6, 2024 | marketbeat.comBeam Therapeutics Bolts Higher on Gene Therapy Licensing PaymentsBeam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in placeMarch 28, 2024 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Receives Outperform Rating from BMO Capital MarketsMarch 27, 2024 | markets.businessinsider.comExpert Outlook: Beam Therapeutics Through The Eyes Of 4 AnalystsMarch 26, 2024 | markets.businessinsider.comBeam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UKMarch 26, 2024 | globenewswire.comBeam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | finance.yahoo.comBeam Therapeutics Inc. (BEAM) Stock Historical Prices & Data - Yahoo FinanceMarch 25, 2024 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Hold" by AnalystsMarch 23, 2024 | msn.comChennia Apollo cancer centre trains international docs in proton beam therapyMarch 22, 2024 | americanbankingnews.comBeam Therapeutics Inc. to Post Q1 2024 Earnings of ($1.25) Per Share, Leerink Partnrs Forecasts (NASDAQ:BEAM)March 21, 2024 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) to Post FY2025 Earnings of ($5.38) Per Share, Leerink Partnrs ForecastsMarch 17, 2024 | usatoday.comTennessee pitcher Drew Beam hit hard by Alabama baseball in 6-3 lossMarch 16, 2024 | finance.yahoo.comBEAM Mar 2024 40.000 putMarch 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)March 1, 2024 | markets.businessinsider.comBeam Therapeutics: Financial and Clinical Prospects Inform Hold RatingMarch 1, 2024 | finance.yahoo.comBeam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To KnowFebruary 29, 2024 | finance.yahoo.comNews Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under ThreatFebruary 29, 2024 | msn.com‘I'm beaming again after brain tumour therapy gave me my life back'February 28, 2024 | markets.businessinsider.comBeam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline DevelopmentsFebruary 28, 2024 | finance.yahoo.comBeam Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 28, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Beam TherapeuticsFebruary 28, 2024 | globenewswire.comBeam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesFebruary 27, 2024 | markets.businessinsider.comWilliam Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)February 27, 2024 | finance.yahoo.comBeam Therapeutics Stock Jumps To Higher RS Level On Earnings BeatSee More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees436Year Founded2017Price Target and Rating Average Stock Price Target$41.00 High Stock Price Target$57.00 Low Stock Price Target$20.00 Potential Upside/Downside+24.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-35.09% Pretax Margin-34.72% Return on Equity-15.90% Return on Assets-9.75% Debt Debt-to-Equity RatioN/A Current Ratio5.89 Quick Ratio5.89 Sales & Book Value Annual Sales$377.71 million Price / Sales7.14 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book2.74Miscellaneous Outstanding Shares81,660,000Free Float78,065,000Market Cap$2.70 billion OptionableOptionable Beta1.80 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 55)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 47)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLICG OncologyNASDAQ:CGONIntellia TherapeuticsNASDAQ:NTLARecursion PharmaceuticalsNASDAQ:RXRXKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 923 shares on 3/22/2024Ownership: 0.002%Vanguard Group Inc.Bought 349,906 shares on 3/11/2024Ownership: 8.774%Wellington Management Group LLPBought 20,916 shares on 3/5/2024Ownership: 0.026%Goldman Sachs Group Inc.Bought 22,433 shares on 3/1/2024Ownership: 0.593%American International Group Inc.Bought 1,218 shares on 2/28/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price target for 2024? 13 equities research analysts have issued 1-year target prices for Beam Therapeutics' stock. Their BEAM share price targets range from $20.00 to $57.00. On average, they expect the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 24.1% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2024? Beam Therapeutics' stock was trading at $27.22 at the beginning of 2024. Since then, BEAM shares have increased by 21.4% and is now trading at $33.04. View the best growth stocks for 2024 here. Are investors shorting Beam Therapeutics? Beam Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 14,320,000 shares, an increase of 9.2% from the February 29th total of 13,110,000 shares. Based on an average trading volume of 1,420,000 shares, the days-to-cover ratio is currently 10.1 days. View Beam Therapeutics' Short Interest. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Tuesday, February, 27th. The company reported $1.73 earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $2.42. The company had revenue of $316.20 million for the quarter, compared to the consensus estimate of $34.16 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 35.09%. The company's revenue for the quarter was up 1481.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.54) EPS. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.53%), Vanguard Group Inc. (8.79%), Vanguard Group Inc. (8.77%), Sumitomo Mitsui Trust Holdings Inc. (2.89%), Nikko Asset Management Americas Inc. (2.89%) and Baillie Gifford & Co. (0.94%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More This page (NASDAQ:BEAM) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.